I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Friday, October 14, 2016
Depression often remains untreated in many Parkinson’s disease patients
Treatment options for patients with Parkinson’s disease and depression
October 14, 2016
Thursday, October 13, 2016
|This is a colorized scanning electron micrograph of a human induced pluripotent stem cell-derived neuron in culture. NeuroscienceNews.com image is credited to Thomas Deerinck, National Center for Microscopy and Imaging Research, UC San Diego.|
Source: Scott LaFee – UCSD
•FAD mutations impair endocytosis and transcytosis of APP and lipoproteins
•Reduced lipoprotein endocytosis and transcytosis are rescued by β-secretase inhibition
We investigated early phenotypes caused by familial Alzheimer’s disease (fAD) mutations in isogenic human iPSC-derived neurons. Analysis of neurons carrying fAD PS1 or APP mutations introduced using genome editing technology at the endogenous loci revealed that fAD mutant neurons had previously unreported defects in the recycling state of endocytosis and soma-to-axon transcytosis of APP and lipoproteins. The endocytosis reduction could be rescued through treatment with a β-secretase inhibitor. Our data suggest that accumulation of β-CTFs of APP, but not Aβ, slow vesicle formation from an endocytic recycling compartment marked by the transcytotic GTPase Rab11. We confirm previous results that endocytosis is affected in AD and extend these to uncover a neuron-specific defect. Decreased lipoprotein endocytosis and transcytosis to the axon suggest that a neuron-specific impairment in endocytic axonal delivery of lipoproteins and other key materials might compromise synaptic maintenance in fAD.
Growblox Sciences Announces Patent Application for Treatments of Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease and Dementia